Van ECK Associates Corp Sells 708,792 Shares of West Pharmaceutical Services, Inc. $WST

Van ECK Associates Corp decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 49.7% during the fourth quarter, HoldingsChannel reports. The firm owned 716,087 shares of the medical instruments supplier’s stock after selling 708,792 shares during the quarter. Van ECK Associates Corp’s holdings in West Pharmaceutical Services were worth $197,025,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Holocene Advisors LP bought a new position in shares of West Pharmaceutical Services in the third quarter valued at approximately $49,085,000. Nordea Investment Management AB grew its stake in shares of West Pharmaceutical Services by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock worth $4,122,000 after acquiring an additional 4,477 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of West Pharmaceutical Services by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock worth $62,163,000 after acquiring an additional 16,919 shares during the last quarter. Birch Hill Investment Advisors LLC grew its stake in shares of West Pharmaceutical Services by 11.5% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock worth $41,862,000 after acquiring an additional 15,678 shares during the last quarter. Finally, DAVENPORT & Co LLC grew its stake in shares of West Pharmaceutical Services by 559.8% in the fourth quarter. DAVENPORT & Co LLC now owns 9,521 shares of the medical instruments supplier’s stock worth $2,620,000 after acquiring an additional 8,078 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $328.33 on Friday. The stock has a 50-day simple moving average of $298.97 and a 200 day simple moving average of $271.63. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12-month low of $206.80 and a 12-month high of $336.82. The stock has a market capitalization of $23.20 billion, a price-to-earnings ratio of 43.89, a P/E/G ratio of 2.76 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

West Pharmaceutical Services declared that its Board of Directors has initiated a stock buyback plan on Tuesday, February 17th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on WST shares. Evercore reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Finally, Morgan Stanley boosted their target price on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services currently has an average rating of “Buy” and an average price target of $340.09.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.